Celcuity (CELC) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celcuity Reports Third Quarter 2019 Financial Results
November 7, 2019 4:01 PM ESTMINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the third quarter ended September 30, 2019.
Unless otherwise stated, all comparisons are for the third quarter ended September 30, 2019, compared to the third quarter ended September 30, 2018.
Celcuity reported a net loss of $1.98 million, or $0.19 per share, for the third quarter of 2019, compared to a net loss of $1.87 million, or $0.18 per share, for... More
